When was Graviton Bioscience founded?

Graviton Bioscience was founded in 2020 and raised its 1st funding round 2 years after it was founded.

Where is Graviton Bioscience located?

Graviton Bioscience is headquartered in New York City, United States.

Who is the current CEO of Graviton Bioscience?

Samuel Waksal of Graviton Bioscience. They have also founded 1 company.

Is Graviton Bioscience a funded company?

Graviton Bioscience is a funded company, having raised a total of $64.8M across 3 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Dec 20, 2022.

When was the latest funding round of Graviton Bioscience?

Graviton Bioscience's latest funding was a $***** Series C round on Feb 01, 2024, with participation from 1 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $732M in funding in 2026 to date.

Where does Graviton Bioscience rank among its competitors?

Graviton Bioscience ranks 222nd amongst 416 active competitors, of which 153 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Graviton Bioscience, which secured an undisclosed amount in Feb, 2024.

Who are the top competitors of Graviton Bioscience?

Graviton Bioscience's top competitors include BioNTech, ADMA Biologics and Nimbus Therapeutics. Among them, Graviton Bioscience secured the most recent funding round in February, 2024.

Graviton Bioscience - 2026 Company Profile, Team, Funding & Competitors

Graviton Bioscience is a series C company based in New York City (United States), founded in 2020 by Samuel Waksal. It operates as a Developer of novel therapeutics for the treatment of autoimmune, cancer, and other serious diseases. Graviton Bioscience has raised $64.8M in funding from Sanofi. The company has 416 active competitors, including 153 funded and 111 that have exited. Its top competitors include companies like BioNTech, ADMA Biologics and Nimbus Therapeutics.

Company Details

Developer of novel therapeutics for the treatment of autoimmune, cancer, and other serious diseases. It offers a lead candidate TDI01 a potent inhibitor of Rho/Rho associated coiled-coil containing protein kinase 2 (ROCK2) for the treatment of idiopathic pulmonary fibrosis.

Website: graviton.bio
Email ID: *****@graviton.bio
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

New York City, United States

Stage

Series C

Total Funding

$64.8M in 3 rounds

Latest Funding Round

Series C, Feb 01, 2024, $*****

Investors

Sanofi

Ranked

222^nd among 416 active competitors

Similar Companies

BioNTech & 485 more

View Graviton Bioscience's full profile

Graviton Bioscience has raised a total funding of $64.8M over 3 rounds. Its first funding round was on Dec 20, 2022. Its latest funding round was a Series C round on Feb 01, 2024 for $*****. 1 investor participated in its latest round. Graviton Bioscience has 1 institutional investor.

Here is the list of recent funding rounds of Graviton Bioscience:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 01, 2024	5806077	Series C	3927756	3202731	8821620	1147316
Nov 22, 2023	9566257	Series C	6562099	4511416	8945665	8276061
Dec 20, 2022	8301603	Series C	8790374	1720194	5750500	1509871

Access funding benchmarks and valuations. Sign up today!

View details of Graviton Bioscience's funding rounds and investors

The founders of Graviton Bioscience is Samuel Waksal. Samuel Waksal is the CEO of Graviton Bioscience.

Here are the details of Graviton Bioscience's key team members:

Samuel Waksal: Founder & CEO of Graviton Bioscience.

View details of Graviton Bioscience's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Graviton Bioscience include BioNTech, ADMA Biologics and Nimbus Therapeutics. Here is the list of Top 10 competitors of Graviton Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Redmile Group, Fidelity Investments & 28 others	72/100
2nd	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	71/100
3rd	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
4th	Apellis Pharmaceuticals 2008, Crestwood (United States), Public	Developer of therapeutics for the treatment of rare diseases	$213M	Sectoral, Hillhouse & 21 others	68/100
5th	PureTech Health 2001, Boston (United States), Public	Developer of immunotherapeutics for multiple diseases	$107M	Vitruvian Partners, Invesco Perpetual	67/100
6th	Cabaletta Bio 2017, Radnor (United States), Public	Developer of CAAR T cells for B cell-mediated autoimmune diseases	$88.3M	Boxer Capital, Deerfield & 5 others	67/100
7th	Vera Therapeutics 2016, San Francisco (United States), Public	Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases	$197M	Abingworth, Citadel & 13 others	66/100
8th	Astria 2008, Boston (United States), Acquired	Developer of therapeutics for rare diseases	$117M	MedImmune Ventures, Perceptive Advisors & 3 others	65/100
9th	Vividion Therapeutics 2016, Oceanside (United States), Acquired	Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers	$271M	Boxer Capital, Logos & 20 others	65/100
10th	Apogee Therapeutics 2022, Waltham (United States), Public	Developer of therapeutics for immunological and inflammatory disorders	$149M	Deep Track Capital, RTW Investments & 5 others	65/100
222nd	Graviton Bioscience 2020, New York City (United States), Series C	Developer of novel therapeutics for the treatment of autoimmune, cancer, and other serious diseases	$64.8M	Sanofi	34/100